MODEL VERDICT
Turn Therapeutics Inc. (TTRX)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Insufficient data to determine relative valuation for TTRX.
Fair value could not be computed for TTRX due to insufficient comparable data.
TTRX's current P/E of N/Ax compares to the industry median of 23.5x (45 peers in the group). This represents a N/A discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: N/A.
1 analysts cover TTRX with a consensus rating of Buy. The consensus price target is N/A (range: N/A — N/A), implying N/A upside from the current price. Grade breakdown: Strong Buy (0), Buy (1), Hold (0), Sell (0), Strong Sell (0).
The model confidence score is 38/100, based on: data completeness (0), peer quality (25), historical depth (5), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows weak agreement across inputs — interpret with caution.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for TTRX.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.